Cybin Inc. - CYBN STOCK NEWS

ALTRD.TV has launched a trailer for its upcoming six-part miniseries, Open Minds: Exploring Psychedelic Medicine, set to premiere in 2023. Featuring industry leaders including Deepak Chopra and Dennis McKenna, the series delves into the resurgence of psychedelic research for mental health treatments. The documentary aims to explore consciousness, the use of psychedelics in therapy, and the future of mental healthcare. Executive Producer Joshua Otten emphasizes the significant impact these treatments could have on global mental health.

Cybin, a biopharmaceutical firm focused on psychedelics, has enhanced its intellectual property portfolio with over 20 active patent filings across six families, including 14 filed this year. Additionally, the company has secured multiple licensing agreements, granting access to more than 35 patents and applications. This strategic move bolsters Cybin’s R&D efforts, particularly in developing novel drug candidates for mental health disorders, such as CYB003 and CYB004.

Cybin has entered an exclusive licensing agreement with Mindset Pharma to acquire a targeted class of tryptamine-based molecules. The agreement includes a one-time payment of $500,000 and potential milestone payments totaling up to $9.5 million. This partnership enhances Cybin's preclinical library and strengthens its intellectual property in psychedelic therapeutics aimed at mental health conditions. The collaboration supports Cybin's long-term goal of developing innovative treatments for areas of high unmet need.

Cybin Inc. (AMEX:CYBN), a biopharmaceutical company specializing in psychedelics, announces its participation in key conferences. Notable events include the Interdisciplinary Conference on Psychedelic Research in Haarlem, Amsterdam from September 21-24, 2022. CEO Doug Drysdale and CMO Amir Inamdar will participate in panel discussions. Cybin will also attend the Jefferies Innovation in Mental Health Summit in New York City on September 22, 2022, and the Cantor Neurology & Psychiatry Conference in San Francisco on October 6-7, 2022. The company aims to create effective mental health therapeutics.

Cybin Inc. (AMEX:CYBN) has successfully achieved key research and development milestones ahead of schedule, transitioning from discovery to clinical-stage development in under two years. This advancement aims to progress its psychedelic drug pipeline, specifically programs CYB003 and CYB004 targeting major depressive and anxiety disorders. Over 200 preclinical studies have been completed, leading to one granted U.S. patent and a robust intellectual property portfolio. The company emphasizes its commitment to creating innovative treatments for mental health issues.

Cybin Inc. has announced the achievement of a significant milestone in its collaboration with Adelia Therapeutics Inc., a wholly-owned subsidiary, as per a contribution agreement dated December 4, 2020. This milestone completion allows for the issuance of 33,190.1 Class B common shares valued at approximately CAD $467,982 to Adelia's shareholders at an effective price of CAD $14.10 per share. Cybin aims to advance its drug development processes and transition into a clinical-stage organization, focusing on developing therapeutics for mental health issues.

Cybin Inc. has commenced its Phase 1/2a clinical trial for CYB003, a novel psilocybin analog aimed at treating major depressive disorder (MDD). The trial marks a significant milestone as it progresses to clinical development only 18 months after initiation. Initial dosing has begun with two participants, reflecting a growing interest and need for innovative mental health treatments. Preclinical studies indicate CYB003 may offer improved efficacy over traditional psilocybin, including reduced variability and faster action. The trial aims to assess safety and effectiveness over a 12-week period.

Cybin, a biopharmaceutical company focused on Psychedelics to Therapeutics, announces that CEO Doug Drysdale will engage in a virtual fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The chat will be available on demand starting September 12, 2022, at 7:00 a.m. ET. Interested parties can access the event and a subsequent archived version via the Company’s investor relations website.

Cybin Inc. has received a Schedule I license from the U.S. Drug Enforcement Agency to commence its Phase 1/2a clinical trial for CYB003, a deuterated psilocybin analog aimed at treating major depressive disorder. CEO Doug Drysdale announced that participant recruitment is underway, with hopes to begin dosing soon. The trial will evaluate the efficacy of CYB003 through a randomized, placebo-controlled study assessing the impact of two doses on moderate to severe MDD. The results will contribute to understanding the drug's potential benefits and safety over a 12-week period.